| Authors: |
Koleva-Kolarova R; Health Economics Research Centre, University of Oxford, Oxford, UK. rositsa.koleva-kolarova@ndph.ox.ac.uk., Hulse E; Government Outcomes Lab, Blavatnik School of Government, University of Oxford, Oxford, UK.; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Németh B; Syreon Research Institute, Budapest, Hungary., Rutten-van Mölken M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., Edwards RT; Centre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Bangor, UK., Babarczy B; Syreon Research Institute, Budapest, Hungary.; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.; Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary., Nagy B; Syreon Research Institute, Budapest, Hungary.; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.; Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary., Wordsworth S; Health Economics Research Centre, University of Oxford, Oxford, UK.; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK., Tsiachristas A; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.; Department of Psychiatry, University of Oxford, Oxford, UK. |
